Ariel Perez Perez
Overview
Explore the profile of Ariel Perez Perez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wood A, Perez A, Arciola B, Patel K, Johnson G, Dimaggio E, et al.
Transplant Cell Ther
. 2022 Sep;
28(12):829.e1-829.e8.
PMID: 36174934
Patients with renal impairment (RI) are typically excluded from trials evaluating chimeric antigen receptor (CAR) T cell therapies. We evaluated the outcomes of patients with RI receiving standard of care...
2.
Lazaryan A, Lee S, Arora M, Kim J, Betts B, Khimani F, et al.
Blood Adv
. 2021 Oct;
6(1):259-269.
PMID: 34649279
Standard initial therapy of chronic graft vs. host disease (cGVHD) with glucocorticoids results in suboptimal response. Safety and feasibility of therapy with ofatumumab (1000 mg IV on days 0 and...
3.
Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, et al.
Transplant Cell Ther
. 2021 Jul;
27(11):940-948.
PMID: 34329754
Post-transplantation cyclophosphamide (PTCy) is being increasingly used for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic cell transplantation (allo-HCT) across various donor types. However, immune reconstitution and infection incidence after PTCy-based...
4.
Khimani F, Dutta M, Faramand R, Nishihori T, Perez A, Dean E, et al.
Transplant Cell Ther
. 2021 Apr;
27(7):620.e1-620.e9.
PMID: 33798768
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment option for patients with acute lymphoblastic leukemia (ALL). Both total body irradiation (TBI)-based and chemotherapy only-based myeloablative transplantation conditioning regimens have...
5.
Kropf J, Gerges M, Perez A, Ellis A, Mathew M, Ayesu K, et al.
Am J Case Rep
. 2020 Jan;
21:e919032.
PMID: 31956261
BACKGROUND Primary effusion lymphoma (PEL) is a rare and aggressive non-Hodgkin lymphoma (NHL) that is responsible for 1% of all lymphomas not related to human immunodeficiency virus (HIV). PEL is...